Chen, San Antonio
Banglin Chen, San Antonio, TX US
Patent application number | Description | Published |
---|---|---|
20100081186 | Self-decontaminating metal organic frameworks - A self-decontaminating metal organic framework including an acid linked to a metal producing a metal organic framework configured for the sorption of chemical warfare agents and/or toxic industrial chemicals, the metal organic framework including reactive sites for the degradation of the agents and chemicals. | 04-01-2010 |
20110269984 | Acetylene storage using metal-organic frameworks of the formula M2(2,5-dihydroxyterephthalate) - This invention provides, but is not limited to, methods of using metal-organic frameworks (MOFs) having repeat units of the formula M | 11-03-2011 |
20110272031 | Isoreticular metal-organic framework of the formula Zn4O(FMA)3 - This invention provides metal-organic frameworks (MOFs) having repeat units of the formula Zn | 11-10-2011 |
20120040471 | Zn4(OH)2(1,2,4-BTC)2 - a rod packing microporous metal-organic framework with open metal sites for selective separation and sensing of small molecules - Disclosed herein are rod-packing robust microporous metal-organic frameworks having the repeat unit Zn | 02-16-2012 |
20130035527 | ACETYLENE STORAGE USING METAL-ORGANIC FRAMEWORKS WITH OPEN METAL SITES - This invention provides, but is not limited to, methods of using metal-organic frameworks (MOFs) with open metal sites for acetylene storage. Also provided are compositions and materials comprising MOFs with open metal sites and acetylene, e.g., an acetylene storage material comprising HKUST-1 and acetylene. | 02-07-2013 |
20130043407 | Zn5(BTA)6(TDA)2 - A ROBUST HIGHLY INTERPENETRATED METAL-ORGANIC FRAMEWORK CONSTRUCTED FROM PENTANUCLEAR CLUSTERS FOR SELECTIVE SORPTION OF GAS MOLECULES - Disclosed herein are highly interpenetrated robust metal-organic frameworks having the repeat unit Zn | 02-21-2013 |
20130123563 | SELF-DECONTAMINATING METAL ORGANIC FRAMEWORKS - A self-decontaminating metal organic framework including an acid linked to a metal producing a metal organic framework configured for the sorption of chemical warfare agents and/or toxic industrial chemicals, the metal organic framework including reactive sites for the degradation of the agents and chemicals. | 05-16-2013 |
20130210157 | Zn3(BDC)3[Cu(SalPycy)] AND Zn3(CDC)3[Cu(SalPycy)] - ENANTIOPURE MIXED METAL-ORGANIC FRAMEWORKS FOR SELECTIVE SEPARATIONS AND ENANTIOSELECTIVE RECOGNITION - Disclosed herein are mixed metal-organic frameworks, Zn | 08-15-2013 |
20140194639 | METAL-ORGANIC FRAMEWORK WITH OPTIMIZED OPEN METAL SITES AND PORE SPACES FOR HIGH METHANE STORAGE AT ROOM TEMPERATURE - A 3D porous metal-organic framework and method of making are described. In some embodiments, a 3D porous metal-organic framework may be based on a trinodal (3,3,4) net of zyg topology by the self-assembly of the nonlinear hexacarboxylate (BHB) with the paddle-wheel Cu | 07-10-2014 |
Chonglin Chen, San Antonio, TX US
Patent application number | Description | Published |
---|---|---|
20130177995 | HIGHLY EPITAXIAL THIN FILMS FOR HIGH TEMPERATURE/HIGHLY SENSITIVE CHEMICAL SENSORS FOR CRITICAL AND REDUCING ENVIRONMENT - An oxygen sensor includes an epitaxial oxide thin film double perovskite oxygen sensor formed on a single crystal oxide substrate. The thin film includes a lanthanide element, barium, cobalt, and oxygen. | 07-11-2013 |
Fernando T. Chen, San Antonio, TX US
Patent application number | Description | Published |
---|---|---|
20130218109 | MULTI-ORIENTATION CANISTER FOR USE WITH A REDUCED PRESSURE TREATMENT SYSTEM - Systems and methods for reduced pressure tissue treatments, including a multi-orientation canister. The canister includes an inlet for receiving fluids from a tissue site, and a main chamber in fluid communication with the inlet for receiving fluids from the inlet. The canister includes a filter chamber separated from the main chamber by one or more filter chamber walls. The one or more filter chamber walls includes a primary hole having a first diameter and a secondary hole having a second diameter smaller than the first diameter. The primary hole provides a first path of fluid communication between the filter chamber and the main chamber. The canister includes an outlet for providing fluid communication between the filter chamber and a reduced pressure source. | 08-22-2013 |
20140303577 | MULTI-ORIENTATION CANISTER FOR USE WITH A REDUCED PRESSURE TREATMENT SYSTEM - Systems and methods for reduced pressure tissue treatments, including a multi-orientation canister. The canister includes an inlet for receiving fluids from a tissue site, and a main chamber in fluid communication with the inlet for receiving fluids from the inlet. The canister includes a filter chamber separated from the main chamber by one or more filter chamber walls. The one or more filter chamber walls includes a primary hole having a first diameter and a secondary hole having a second diameter smaller than the first diameter. The primary hole provides a first path of fluid communication between the filter chamber and the main chamber. The canister includes an outlet for providing fluid communication between the filter chamber and a reduced pressure source. | 10-09-2014 |
Rainbow Chen, San Antonio, TX US
Patent application number | Description | Published |
---|---|---|
20110003775 | COMPOSITION AND METHOD FOR PROMOTING SURVIVAL OF AGED BASAL FOREBRAIN CHOLINERGIC NEURON LEADING TO PROVENTION AND TREATMENT OF AGE-RELATED NEURODEGENERATIVE DISORDER - A method of treating a subject and preventing in a subject age-dependent basal forebrain cholinergic dysfunction related neurodegenerative disorders, comprising: administering a lipid composition comprising a therapeutically effective amount of highly enriched 1-acyl chains/2-docosahexaenoic acid containing molecular species of highly pure phospholipids to promote survival of aged basal forebrain cholinergic neurons, the phospholipids selected from the group consisting of phosphatidylserine, phosphatidylethanolamine, and phosphatidyl-monomethylethanolamine. A composition for treating a subject and preventing in a subject age-dependent basal forebrain cholinergic dysfunction related neurodegenerative disorders, the composition comprising: a lipid composition comprising: a therapeutically effective amount of highly enriched 1-acyl chains/2-docosahexaenoic acid containing molecular species of highly pure phospholipids to promote survival of aged basal forebrain cholinergic neurons, the phospholipids selected from the group consisting of phosphatidylserine, phosphatidylethanolamine, and phosphatidyl-monomethylethanolamine. A process for preparing a lipid composition comprising a therapeutically amount of natural source-based highly enriched 1-acyl chains/2-docosahexaenoic acid containing molecular species of highly pure phosphatidylserine to promote survival of aged basal forebrain cholinergic neurons; the process comprising: purifying a natural source-based phosphatidylcholine by silica chromatography; obtaining a related lysophosphatidylserine species by phospholipase A2 catalysis of transphosphatidylated natural source-based phosphatidylserine species; acylating the lysophosphatidylserine species with natural docosahexaenoic acid to form 1-acyl chains/2-docosahexaenoic acid containing phosphatidylserine species; and purifying the 1-acyl cgains/2-docosahexaenoic acid containing phosphatidylserine species by silica chromatography. | 01-06-2011 |
Su Chen, San Antonio, TX US
Patent application number | Description | Published |
---|---|---|
20110003775 | COMPOSITION AND METHOD FOR PROMOTING SURVIVAL OF AGED BASAL FOREBRAIN CHOLINERGIC NEURON LEADING TO PROVENTION AND TREATMENT OF AGE-RELATED NEURODEGENERATIVE DISORDER - A method of treating a subject and preventing in a subject age-dependent basal forebrain cholinergic dysfunction related neurodegenerative disorders, comprising: administering a lipid composition comprising a therapeutically effective amount of highly enriched 1-acyl chains/2-docosahexaenoic acid containing molecular species of highly pure phospholipids to promote survival of aged basal forebrain cholinergic neurons, the phospholipids selected from the group consisting of phosphatidylserine, phosphatidylethanolamine, and phosphatidyl-monomethylethanolamine. A composition for treating a subject and preventing in a subject age-dependent basal forebrain cholinergic dysfunction related neurodegenerative disorders, the composition comprising: a lipid composition comprising: a therapeutically effective amount of highly enriched 1-acyl chains/2-docosahexaenoic acid containing molecular species of highly pure phospholipids to promote survival of aged basal forebrain cholinergic neurons, the phospholipids selected from the group consisting of phosphatidylserine, phosphatidylethanolamine, and phosphatidyl-monomethylethanolamine. A process for preparing a lipid composition comprising a therapeutically amount of natural source-based highly enriched 1-acyl chains/2-docosahexaenoic acid containing molecular species of highly pure phosphatidylserine to promote survival of aged basal forebrain cholinergic neurons; the process comprising: purifying a natural source-based phosphatidylcholine by silica chromatography; obtaining a related lysophosphatidylserine species by phospholipase A2 catalysis of transphosphatidylated natural source-based phosphatidylserine species; acylating the lysophosphatidylserine species with natural docosahexaenoic acid to form 1-acyl chains/2-docosahexaenoic acid containing phosphatidylserine species; and purifying the 1-acyl cgains/2-docosahexaenoic acid containing phosphatidylserine species by silica chromatography. | 01-06-2011 |
20110124061 | METHOD FOR PREPARATION OF POLYUNSATURATED FATTY ACID-CONTAINING PHOSPHATIDYLSERINE - A method for the preparation of the polyunsaturated fatty acids-containing phosphatidylserine, the method comprising: combining L-serine with a fish liver phosphatidylcholine having a polyunsaturated fatty acid to form a mixture; reacting the mixture with phospholipase D to effect transphosphatidylation of L-serine and the phosphatidylcholine having polyunsaturated fatty acids to produce the polyunsaturated fatty acids-containing phosphatidylserine. | 05-26-2011 |
Xiaoyu Chen, San Antonio, TX US
Patent application number | Description | Published |
---|---|---|
20140127320 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS - A composition and method adapted for delivery of hydrophilic, biologically-active agents are disclosed. The composition can include a reverse microemulsion formed from at least one hydrophilic, biologically-active agent solubilized by a hydrophobic reverse emulsion surfactant in a non-stinging, volatile, hydrophobic solvent. The non-stinging, volatile, hydrophobic solvent is selected from the group consisting of volatile linear and cyclic siloxanes, volatile linear, branched, and cyclic alkanes, volatile fluorocarbons and chlorofluorocarbons, liquid carbon dioxide under pressure, and combinations thereof. The reverse microemulsion can be an optically clear solution. | 05-08-2014 |
Xinghai Chen, San Antonio, TX US
Patent application number | Description | Published |
---|---|---|
20090099166 | C10-substituted camptothecin analogs - The novel C10-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600). | 04-16-2009 |
20090099224 | C7- substituted camptothecin analogs - The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600). | 04-16-2009 |
20120282261 | Deuterated analogs of (4S)-4-Ethyl-4-hydroxy-11-[2- (trimethylsilyl)ethyl]-1H-pyrano[3', 4':6,7] indolizino [1,2-b]quinoline-3,14(4H, 12H)-dione and methods of use thereof - The present invention discloses: (i) two novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (ii) methods of synthesis of said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (iii) pharmaceutically-acceptable formulations comprising said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents; and (iv) methods of administration of said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof. | 11-08-2012 |
20140073793 | Germanium-containing camptothecin analogues - The present invention discloses: (i) the novel germanium-containing camptothecin compound, 7[2′-trimethylgermanyl]ethyl-20(S) camptothecin, and pharmaceutically-acceptable salts thereof; (ii) methods of synthesis of said novel germanium-containing camptothecin compound, 7[2′-trimethylgermanyl]ethyl-20(S) camptothecin, and pharmaceutically-acceptable salts; (iii) pharmaceutically-acceptable formulations comprising said novel germanium-containing camptothecin compound, 7[2′-trimethylgermanyl]ethyl-20(S) camptothecin, and pharmaceutically-acceptable salts thereof; and (iv) methods of administration of said novel germanium-containing camptothecin compound, 7[2′-trimethylgermanyl]ethyl-20(S) camptothecin, and pharmaceutically-acceptable salts thereof to subjects in need thereof, including subjects with cancer. | 03-13-2014 |
20140135499 | METHODS FOR THE TOTAL CHEMICAL SYNTHESIS OF ENANTIOMERICALLY-PURE 7-(2'-TRIMETHYLSILYL) ETHYL CAMPTOTHECIN - The present invention discloses and claims five (5) novel, highly efficient synthetic routes for the total synthesis of enantiomerically-pure (i.e., 99%) 7-(2′-trimethylsilyl)ethyl camptothecin (BNP1350; Karenitecin; Cositecan). These aforementioned synthetic schemes are the first to disclose the total syntheses of 7-(2′-trimethylsilyl)ethyl camptothecin using a highly novel direct, non-linear and convergent synthetic strategy which involves annealing the key C7-(trimethylsilyl)ethyl side chain-bearing A ring key synthons to an enantiomerically-pure tricyclic pyridone; rather than through the conventional methodology which incorporates the C7-(trimethylsilyl)ethyl side chain as the final synthetic step on a totally synthesized camptothecin parent compound. The current novel synthetic approaches reported herein since utilize desirably functionalized A-ring with preinstalled trimethyl silyl ethyl side chain, the aforementioned synthetic methodologies have a wider scope of making wide range of pharmaceutically relevant A-ring substituted BNP1350 analogs by substituting desirably functionalized nitro or protected amino phenyl carboxy A-ring as the starting material. | 05-15-2014 |
Yong Xin Chen, San Antonio, TX US
Patent application number | Description | Published |
---|---|---|
20090192108 | Gene overexpressed in cancer - Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer. | 07-30-2009 |
20110082284 | Gene overexpressed in cancer - Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer. | 04-07-2011 |